Blog

Jayastu Senapati: Check out our poster on display at ASH23

Photo from Jayastu Senapati/X

Dec 15, 2023, 06:27

Jayastu Senapati: Check out our poster on display at ASH23

Jayastu Senapati, Assistant Professor at the Department of Leukemia at MD Anderson Cancer Center, shared on X/Twitter:

“Check out our poster on display today at the American Society of Hematology (ASH23).
-High-risk cytogenetics (HG-CTG) loses prognostic impact with inotuzumab ozogamicin (InO) and blinatumomab (Blina) added to frontline HyperCVAD chemotherapy in newly diagnosed patients with Philadelphia negative B-cell Acute Lymphoblastic Leukemia.
-Further analysis underway.”

Source: Jayastu Senapati/X

Acute Lymphoblastic Leukemia American Society of Hematology ASH23 blinatumomab cancer High-risk cytogenetics (HG-CTG) HyperCVAD inotuzumab ozogamicin Jayastu Senapati MD Anderson Cancer Center OncoDaily Oncology

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage